Every 10-K that Biomerica Inc (BMRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BMRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMRA filings page.
Biomerica, Inc. (BMRA) reports that fiscal 2026 was marked by commercialization of its inFoods® IBS and hp+detect™ diagnostics but also by financial strain and declining sales. Net sales were $4.45 million for the year ended May 31, 2026, down about 16% from 2025, driven partly by distributor ordering patterns and shipment timing. One distributor represented 31% of net sales, and a small group of distributors represented most receivables, underscoring customer concentration risk.
The company invests in diagnostic-guided therapy via the inFoods® IBS product, which uses a blood test to identify symptom‑triggering foods; a clinical study was published in Gastroenterology and CMS set a $300 Medicare payment rate effective January 1, 2026. Biomerica also launched hp+detect™ for H. pylori, received FDA 510(k) clearance and its first commercial order from a large European lab chain.
Despite these advances, Biomerica has a history of losses and negative operating cash flows. Management states that existing cash is insufficient to fund operations for the next 12 months, and the auditor included a going‑concern explanatory paragraph. The company raised about $1.83 million via its ATM program, reduced R&D spending, and continues cost controls while facing significant regulatory, international, reimbursement and competitive risks.
Biomerica, Inc. (BMRA) filed an amendment to its annual report (Form 10-K/A) that discloses corporate governance, executive compensation and equity ownership details. The filing states a 1-for-8 reverse stock split became effective on April 21, 2025, and reports 2,869,900 shares outstanding as of September 26, 2025, producing an implied market value of approximately $6.4 million based on a $3.12 closing price. The document lists the board and executive officers, shows 2024 and 2025 cash and equity compensation for named executives, and details option grants and exercisable options for each named person, with executives and directors as a group beneficially owning 16.2% of the company on a post-split basis.
Biomerica, Inc. (BMRA) reported a net loss of $4,973,000 for fiscal 2025 compared with a $5,978,000 loss in fiscal 2024, showing an improvement in operating results. The company had cash and cash equivalents of approximately $2,399,000 and working capital of about $3,135,000 at May 31, 2025, versus $4,170,000 cash and $5,527,000 working capital a year earlier, indicating reduced liquidity. During the year the company completed ATM sales of 440,687 shares for gross proceeds of ~$2,143,000 and net proceeds of ~$2,015,000. Revenue mix included over-the-counter sales of $1,049,000 and contract manufacturing of $1,070,000, with two distributors accounting for 41% of net sales in 2025. The company’s common stock trades on the Nasdaq Capital Market under the symbol BMRA and a 1-for-8 reverse split became effective April 21, 2025.